相关实验视频
Updated: May 27, 2025

11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.3K
在状癌中,MLL3/GRHL2复合体调节恶性转变和抗瘤免疫力
Chehyun Nam1, Guowei Huang2,3, Yueyuan Zheng2
1Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.
The Journal of experimental medicine
|February 18, 2025
概括
MLL3基因突变驱动早期上空气消化状细胞癌 (UASCC) 的发展. 这种MLL3/GRHL2通路增强了抗瘤免疫力,并预测了UASCC患者对免疫检查点阻塞 (ICB) 治疗的反应.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 上部气消化层状细胞癌 (UASCC) 是积极的,具有挑战性的管理.
- 了解早期遗传驱动因素对于开发有效的治疗方法至关重要.
研究的目的:
- 研究MLL3突变在UASCC瘤发生中的作用.
- 探索MLL3/GRHL2复合体在调节瘤表观基因组和免疫反应方面的功能.
- 评估MLL3对免疫检查点阻断 (ICB) 治疗疗效的影响.
主要方法:
- 用CRISPR编辑的跨物种有机体建模来研究MLL3功能丧失.
- 识别MLL3/GRHL2蛋白质复合体及其下游目标.
- 对MLL3表达的分析与患者对ICB治疗的反应有关.
主要成果:
- MLL3突变是早期的克隆事件,启动了UASCC的发展.
- 失去MLL3促进了早期状瘤的演变.
- MLL3/GRHL2复合体调节UASCC表观基因组,通过MLL3/GRHL2-IRF1轴影响免疫路径.
- 这个轴通过促进T细胞透来增强抗瘤免疫力.
- MLL3表达与患者对ICB治疗的反应相关.
结论:
- MLL3突变是UASCC的基本驱动因素.
- MLL3/GRHL2复合体及其对免疫通路的调节代表了UASCC的潜在治疗标.
- 在UASCC中,MLL3状态是ICB治疗反应的预测生物标志物.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K

